Dr. Ready is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
20 Duke Medicine Circle
Durham, NC 27710Phone+1 919-660-9674- Is this information wrong?
Education & Training
- Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1992 - 1994
- Roger Williams Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1992
- Brown UniversityResidency, Internal Medicine, 1986 - 1989
- Vanderbilt University School of MedicineClass of 1986
Certifications & Licensure
- NC State Medical License 2006 - 2024
- RI State Medical License 1988 - 2006
- MA State Medical License 1994 - 2003
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2010-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- America's Top Doctors for Cancer Castle Connolly, 2009-2013
Clinical Trials
- Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Start of enrollment: 2002 May 01
- Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer Start of enrollment: 2004 Dec 01
- Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2007 Mar 15
- Join now to see all
Publications & Presentations
PubMed
- Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity.Hong Zheng, Xiaoqing Yu, Mohammed L Ibrahim, Dana Foresman, Mengyu Xie, Joseph O Johnson, Theresa A Boyle, Brian Ruffell, Bradford A Perez, Scott J Antonia, Neal Ready...> ;Cancer Immunology Research. 2023 Apr 3
- 12 citationsFirst-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckM...Neal E Ready, Clarisse Audigier-Valette, Jonathan W Goldman, Enriqueta Felip, Tudor-Eliade Ciuleanu, María Rosario García Campelo, Kevin Jao, Fabrice Barlesi, Stéphani...> ;Journal for Immunotherapy of Cancer. 2023 Feb 1
- 1 citationsPatient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study.Monica H Bodd, Susan C Locke, Steve P Wolf, Scott Antonia, Jeffrey Crawford, John Hartman, Kris W Herring, Neal E Ready, Thomas E Stinchcombe, Jesse D Troy, Chakita Wi...> ;Lung Cancer. 2023 Jan 1
- Join now to see all
Press Mentions
- Targeting Innovation in Small Cell Lung CancerNovember 29th, 2018
Professional Memberships
- Member
Hospital Affiliations
- Duke University HospitalDurham, North Carolina
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: